Angiogenic inhibition in high-grade gliomas: past, present and future

High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?

(2011) J. F. de Groot   CLINICAL CANCER RESEARCH

Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept

(2011) J. F. de Groot et al.   CLINICAL CANCER RESEARCH

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis

(2011) Robert A. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

(2011) T. N. Kreisl et al.   NEURO-ONCOLOGY

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

(2011) J. S. Wefel et al.   NEURO-ONCOLOGY

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab

(2011) W. B. Pope et al.   NEUROLOGY

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

(2011) Olivier Keunen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions

(2011) J D Lathia et al.   Cell Death & Disease

Bevacizumab does not increase the risk of remote relapse in malignant glioma

(2010) Antje Wick et al.   ANNALS OF NEUROLOGY

Potential therapeutic implications of cancer stem cells in glioblastoma

(2010) Lin Cheng et al.   BIOCHEMICAL PHARMACOLOGY

Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas

(2010) Juan L Garcia et al.   BMC CANCER

Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis

(2010) Roberto Pallini et al.   CANCER

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

(2010) Alessandra B. Francesconi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma

(2010) E. Essock-Burns et al.   NEURO-ONCOLOGY

Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study

(2010) J. J. Vredenburgh et al.   ONCOLOGIST

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1

(2009) C. Folkins et al.   CANCER RESEARCH

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms

(2009) Hrvoje Miletic et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

(2009) Rajan Jain et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Antiangiogenic therapies for high-grade glioma

(2009) Andrew D. Norden et al.   Nature Reviews Neurology

Bevacizumab and irinotecan for recurrent oligodendroglial tumors

(2009) S. Taillibert et al.   NEUROLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

(2008) Felix Bokstein et al.   CANCER

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

(2008) Rose Du et al.   CANCER CELL

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

(2008) A. Desjardins et al.   CLINICAL CANCER RESEARCH

The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†

(2008) David A. Reardon et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

(2008) Tyler Y. Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases

(2008) Sheikh A. Ali et al.   JOURNAL OF NEUROSURGERY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

High-grade glioma before and after treatment with radiation and Avastin: Initial observations

(2008) Ingeborg Fischer et al.   NEURO-ONCOLOGY

VEGF Trap induces antiglioma effect at different stages of disease

(2008) Candelaria Gomez-Manzano et al.   NEURO-ONCOLOGY

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

(2008) Qingyu Zhou et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

VEGF Inhibition and Renal Thrombotic Microangiopathy

(2008) Vera Eremina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab

(2008) Carolyn Fein Levy et al.   PEDIATRIC BLOOD & CANCER